HomeCompareMRNS vs YUM

MRNS vs YUM: Dividend Comparison 2026

MRNS yields 363.64% · YUM yields 1.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRNS wins by $5743.61M in total portfolio value
10 years
MRNS
MRNS
● Live price
363.64%
Share price
$0.55
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5743.72M
Annual income
$3,727,348,542.31
Full MRNS calculator →
YUM
YUM
● Live price
1.85%
Share price
$155.48
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.0K
Annual income
$39,957.33
Full YUM calculator →

Portfolio growth — MRNS vs YUM

📍 MRNS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMRNSYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MRNS + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MRNS pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MRNS
Annual income on $10K today (after 15% tax)
$30,909.09/yr
After 10yr DRIP, annual income (after tax)
$3,168,246,260.96/yr
YUM
Annual income on $10K today (after 15% tax)
$157.45/yr
After 10yr DRIP, annual income (after tax)
$33,963.73/yr
At 15% tax rate, MRNS beats the other by $3,168,212,297.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MRNS + YUM for your $10,000?

MRNS: 50%YUM: 50%
100% YUM50/50100% MRNS
Portfolio after 10yr
$2871.91M
Annual income
$1,863,694,249.81/yr
Blended yield
64.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

MRNS
Analyst Ratings
9
Buy
9
Hold
Consensus: Buy
Price Target
$3.67
+567.3% upside vs current
Range: $2.00 — $6.00
Altman Z
-20.1
Piotroski
3/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+11.4% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MRNS buys
0
YUM buys
0
No recent congressional trades found for MRNS or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMRNSYUM
Forward yield363.64%1.85%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$5743.72M$107.0K
Annual income after 10y$3,727,348,542.31$39,957.33
Total dividends collected$5553.13M$80.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyHold
Analyst price target$3.67$173.15

Year-by-year: MRNS vs YUM ($10,000, DRIP)

YearMRNS PortfolioMRNS Income/yrYUM PortfolioYUM Income/yrGap
1← crossover$47,064$36,363.64$10,980$280.44+$36.1KMRNS
2$210,302$159,944.39$12,185$435.72+$198.1KMRNS
3$892,974$667,950.29$13,722$684.14+$879.3KMRNS
4$3,606,147$2,650,664.49$15,773$1,090.14+$3.59MMRNS
5$13,862,620$10,004,043.59$18,650$1,773.02+$13.84MMRNS
6$50,774,301$35,941,297.46$22,921$2,966.37+$50.75MMRNS
7$177,357,815$123,029,312.28$29,685$5,158.69+$177.33MMRNS
8$591,407,528$401,634,666.71$41,216$9,453.02+$591.37MMRNS
9$1,884,459,023$1,251,652,967.55$62,672$18,571.31+$1884.40MMRNS
10$5,743,719,697$3,727,348,542.31$107,016$39,957.33+$5743.61MMRNS

MRNS vs YUM: Complete Analysis 2026

MRNSStock

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Full MRNS Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this MRNS vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MRNS vs SCHDMRNS vs JEPIMRNS vs OMRNS vs KOMRNS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.